The Fusion Antibodies Team will be attending BioJapan 2016 held in Pacifico Yokohama, Japan this October.
BioJapan is Asia’s Leading Bio, Pharma R&D Event (Exhibition, Partnering, Conference) specialised in Biotechnology, Drug Discovery, Pharmaceutical Development, Regenerative Medicine and Personalised Medicine. Japan is the world’s 2nd largest pharmaceuticals and medical devices market. Japan is also recognised as leading the world in the regenerative medicine and cell therapy sector by easing regulations to allow early access to the market.
BioJapan has played a vital role in facilitating interaction between companies and organizations from Japan and abroad for almost 20 years. BioJapan 2016 is expected to feature 8000 partnering meetings, 15000 visitors and 800 participating companies.
The Fusion Team (Dr Paul Kerr and Dr Richard Buick) will be attending from October 12th to 14th.
“I am looking forward to visiting Japan as it’s researchers are at the forefront of many new exciting immunotherapy treatments. Fusion has many collaborators in Japan and I am looking forward to meeting them in person and build on our relationship with Japanese researchers at BioJapan”
Paul Kerr. Managing Director at Fusion Antibodies
To find out more information about BioJapan, please visit http://www.ics-expo.jp/biojapan/index.html
To find out more information about Fusion Antibodies, please visit http://fusionantibodies.com/